Canadian investment bank group: Maintains buy rating on Seres Therapeutics (MCRB.US), adjusting from buy rating to buy rating, with target price adjusted from $15.00 to $10.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.